Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of Depoxythilone (UTD1) in advanced solid tumors
ChiCTR-TNC-09000493Phase 4Completed
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2007
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of utidelone in Nonhematologic neoplasms, breast cancer, colorectal cancer (CRC) and 3 more (6 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Adverse events, Safety and 1 more. Started Oct 2007; status: completed.
02
Drugs
utidelone
03
Conditions
Nonhematologic neoplasmsbreast cancercolorectal cancer (CRC)liver cancergastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-TNC-09000493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-09000493.